No Data
No Data
Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) Investors Are Less Pessimistic Than Expected
When close to half the companies in China have price-to-earnings ratios (or "P/E's") below 31x, you may consider Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) as a stock to avoid entirely
Express News | Pien Tsai and others set up a life and health technology partnership with an investment of 10 million
Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Shareholders Have Earned a 17% CAGR Over the Last Five Years
Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) shareholders might be concerned after seeing the share price drop 12% in the last quarter. But that doesn't change the fact that shareholde
Express News | Jiulongjiang Group: Adding another 830,000 shares of Pien Tsai as “21 Jiulongjiang MTN002 (green)” pooled assets
Is Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Latest Stock Performance A Reflection Of Its Financial Health?
Zhangzhou Pientzehuang Pharmaceutical's (SHSE:600436) stock is up by a considerable 15% over the past week. Given the company's impressive performance, we decided to study its financial indicators m
Pien Tsai (600436): Product sales are improving, and performance is growing steadily
Key points of investment are expected to achieve a net profit growth rate of no less than 25% in the first quarter of 2024. During the beginning of 2024, the company's product sales momentum improved, the market showed a strong sales trend, and successfully achieved a “good start”. The company started with the market
No Data